Skip to main content

BIOTRICITY INC.

corporate_fare Company Profile

BIOTRICITY INC.

BTCY·OTC·Life Sciences·CIK 0001630113

BIOTRICITY INC. is a medical technology company that provides biometric data monitoring solutions. The company delivers remote monitoring solutions to the medical, healthcare, and consumer markets, concentrating on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. For diagnostic remote patient monitoring, BIOTRICITY INC. applies innovation within existing business models where reimbursement is established. In post-diagnostic markets, the company aims to use medical-grade biometrics to enable consumers to self-manage. BIOTRICITY INC. initially focused on the ambulatory diagnostic cardiac outpatient market, specifically Mobile Cardiac Outpatient Monitoring ("COM"), while also offering capabilities for all types of ambulatory cardiac studies. The company developed its Bioflux® ("Bioflux") COM technology, which includes a monitoring device and software components and has received clearance from the U.S. Food and Drug Administration ("FDA"). Bioflux was released in a limited capacity on April 6, 2018, to assess sales processes and market dynamics, with a full market release for commercialization occurring in April 2019. The fiscal year ended March 31, 2021, was the first year of expanded commercialization efforts for Bioflux, focusing on sales growth and expansion. In 2021, the company launched Bioheart, a direct-to-consumer heart monitor that utilizes the same continuous heart monitoring technology as Bioflux. In 2022, BIOTRICITY INC. launched its Biocore Cardiac Monitoring Device ("Biocore", previously branded as Biotres), a three-lead device for ECG and arrhythmia monitoring designed for lower-risk patients. Late in 2024, the company launched the cellular version of this device, the Biocore Pro, which is now its flagship technology.

BIOTRICITY INC. (OTC:BTCY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for BTCY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for BTCY spans 10-Q, 10-K, DEF 14C, PRE 14C.

Recent high-impact activity:

  • Biotricity Q2 Revenue Climbs 11.5% as Gross Margin Widens to 83.3%
  • Biotricity Q1 FY2027: Revenue Climbs 10%, Yet Going Concern and Series C Exchange Loom
  • Biotricity Posts First Operating Profit, Revenue Jumps 16% to $16M
  • Biotricity 10-K: Going Concern Warning Despite Operating Turnaround; 1-for-100 Reverse Split Pending
  • Biotricity Confirms Aggressive 1-for-100 Reverse Stock Split

Financial Snapshot

Fiscal year ended March 31, 2026
Revenue
$16M
Net Income
-$2.4M
Diluted EPS
-$0.12
Op. Cash Flow
-$718.96K
Gross Profit
$12.95M
Operating Income
$1.69M
Cash & Equivalents
$149.79K
Debt / Equity
0.00×
Net Margin
-15.0%
Shares Outstanding
28.6M sh
Source: 10-K · filed 2026-07-14 · accession 0001493152-26-033207

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 118,661 shares in BTCY as of the October 30, 2026 settlement, a 0.3% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 69.8% of BTCY volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)118,661 shares as of October 30, 2026
Change vs prior period▼ 0.3%
Days to cover1.00 at avg daily volume of 163,636
Daily short volume (FINRA facilities)69.8% of 101,483 shares on November 20, 2026
5-day average short volume40.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with B →
$0.059 +31.22% today
52-week range · as of 2026-08-19 $0.059 – $0.7536
Market cap
$1.29M
Volume
101.5K (1.4× avg)
3-mo avg 72.6K
Live data · 2026-11-22 03:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BTCY - Latest Insights

BTCY
Nov 20, 2026, 8:45 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.045
Real-time Price: $0.05905 info
Change: +$0.01405 (+31%) info
Market Cap: $1.287M info
BTCY
Aug 19, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.1208
Real-time Price: $0.05905 info
Change: -$0.06175 (-51%) info
Market Cap: $1.287M info
BTCY
Jul 14, 2026, 5:35 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.09919
Real-time Price: $0.05905 info
Change: -$0.04014 (-40%) info
Market Cap: $1.287M info
BTCY
Jul 14, 2026, 5:25 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.09919
Real-time Price: $0.05905 info
Change: -$0.04014 (-40%) info
Market Cap: $1.287M info
BTCY
Jun 15, 2026, 7:18 PM EDT
Filing Type: DEF 14C
Importance Score:
8
Price at Filing: $0.1355
Real-time Price: $0.05905 info
Change: -$0.07645 (-56%) info
Market Cap: $1.287M info
BTCY
May 29, 2026, 4:05 PM EDT
Filing Type: PRE 14C
Importance Score:
9
Price at Filing: $0.131
Real-time Price: $0.05905 info
Change: -$0.07195 (-55%) info
Market Cap: $1.287M info
BTCY
May 01, 2026, 5:33 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.2628
Real-time Price: $0.05905 info
Change: -$0.20375 (-78%) info
Market Cap: $1.287M info
BTCY
May 01, 2026, 5:28 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.2628
Real-time Price: $0.05905 info
Change: -$0.20375 (-78%) info
Market Cap: $1.287M info
BTCY
Feb 11, 2026, 4:29 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.240
Real-time Price: $0.05905 info
Change: -$0.18095 (-75%) info
Market Cap: $1.287M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets